Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash & Current Investments (2022 - 2025)

Praxis Precision Medicines has reported Cash & Current Investments over the past 4 years, most recently at $599.3 million for Q4 2025.

  • Quarterly results put Cash & Current Investments at $599.3 million for Q4 2025, up 52.67% from a year ago — trailing twelve months through Dec 2025 was $599.3 million (up 52.67% YoY), and the annual figure for FY2025 was $599.3 million, up 52.67%.
  • Cash & Current Investments for Q4 2025 was $599.3 million at Praxis Precision Medicines, up from $267.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for PRAX hit a ceiling of $599.3 million in Q4 2025 and a floor of $56.0 million in Q2 2022.
  • Median Cash & Current Investments over the past 4 years was $165.9 million (2023), compared with a mean of $215.6 million.
  • Biggest five-year swings in Cash & Current Investments: surged 382.86% in 2024 and later dropped 25.17% in 2025.
  • Praxis Precision Medicines' Cash & Current Investments stood at $61.6 million in 2022, then surged by 31.95% to $81.3 million in 2023, then surged by 382.86% to $392.6 million in 2024, then surged by 52.67% to $599.3 million in 2025.
  • The last three reported values for Cash & Current Investments were $599.3 million (Q4 2025), $267.2 million (Q3 2025), and $301.3 million (Q2 2025) per Business Quant data.